Written by Michael Stocker
Spoon Feed
A novel multi-drug treatment protocol for fentanyl/xylazine “tranq dope” withdrawal did not result in clinically significant increases in QTc. However, less than half of the patients adhered to the protocol.
Circumventing cardiac complications complicating complicated cessation
As the opioid epidemic continues to evolve, finding withdrawal treatment options for emerging combination drugs like xylazine (tranq) is vital to safe and effective ED management. QT prolongation is a known complication of many illicit substances and withdrawal regimens. Can this risk be mitigated to reduce the chance of causing harm to these patients?
This retrospective cohort study of 284 adult patients presenting to two urban EDs investigated the electrophysiologic safety of a novel treatment regimen for concomitant opioid and alpha-2 agonist withdrawal. The primary outcome was QT interval and incidence of dysrhythmia, with secondary outcomes including Clinical Opiate Withdrawal Scale (COWS) measurement, individual medication associated with QT prolongation, and other adverse events. The treatment protocol included four pathways (see below).
Ultimately, none of the pathways were found to be associated with clinically significant QTc prolongation, and there were no post-treatment incidences of serious dysrhythmia. Unfortunately, sample size and generalizability were limited due to the pre-/post-treatment ECG requirement selecting almost exclusively (96%) for admitted patients. Roughly 32% of post-treatment ECGs occurred over 24 hours after treatment. Furthermore, only 40% of patients’ treatments adhered to one of the pathways, with the majority receiving partial regimens or noncompliant dosing.
How will this change my practice?
Given the limitations, I’m not convinced this protocol is proven safe from an electrophysiologic standpoint; yet, the data on the safety of individual drugs in the protocol, such as droperidol, is encouraging. Nearly half the cohort had pretreatment prolonged QTc, reinforcing my concern for further prolongation when selecting treatment. Xylazine is spreading, so check out this JF summary evaluating the effectiveness of this treatment protocol.
Source
Assessing the Cardiac Safety of a Multimodal Protocol for ‘Tranq Dope’ Withdrawal: A Retrospective QTc Analysis. Am J Emerg Med. 2026 Jan;99:313-324. doi: 10.1016/j.ajem.2025.10.033. Epub 2025 Oct 17. PMID: 41151217.
View JournalFeed Critical Appraisal
Critical Appraisal
Study Identification
Background
Study Question
Study Design & Conduct
Prospective / Retrospective: Retrospective
Multicenter: Yes
Unit of Allocation: Not applicable
Unit of Analysis: Patients
Randomization Method: Not applicable
Allocation Concealment: Not applicable
Blinding: Not applicable
Follow-up Duration: Not reported
Population
- Adult ED patients
- Suspected fentanyl/xylazine exposure
- Treated using the novel protocol
- Pre- and post-treatment ECGs available
- Received medications before initial ECG
- No second ECG during hospital stay
- Under 18 years of age
- Pregnant
- Suffered ventricular dysrhythmia prior to treatment
Number Enrolled: 284
Number Analyzed: 284
Key Baseline Characteristics
Sex: 62.3% male
Disease Severity: Not reported
Care Setting Distribution: Emergency departments
Additional Baseline Characteristics
- 98.5% positive for fentanyl
- 63.8% positive for cocaine
Exposures / Interventions
Description: Multimodal protocol for 'tranq dope' withdrawal
Definition / Dose: Concurrent use of short-acting opioids, ketamine, dopamine antagonists, and alpha-2 agonists
Timing: During ED visit
Classification Method: Protocolized
Protocolized / Discretionary: Protocolized
Description: Not applicable
Definition: Not applicable
Outcomes & Results
Primary Outcomes
Definition: Difference in QTc interval pre- and post-treatment
Time Point: During ED stay
Measurement Method: ECG
Results: Mean QTc changed from 457 ms pre-treatment to 456 ms post-treatment
Secondary Outcomes
Definition: Change in Clinical Opiate Withdrawal Scale (COWS) scores
Time Point: During ED stay
Measurement Method: COWS
Results: Mean reduction 10 points, p < 0.001
Definition: Association of individual medications with QTc change
Time Point: During ED stay
Measurement Method: ECG
Results: Vancomycin (+13 ms), ondansetron (+16 ms), and methadone (+15 ms) associated with QTc increase
Definition: Incidence of life-threatening arrhythmias
Time Point: During ED stay
Measurement Method: Clinical observation
Results: No life-threatening arrhythmias observed
Risk of Bias
Risk of Bias - ROBINS-I
- Confounding (Some concerns): Potential confounders not fully controlled due to retrospective design.
- Selection of participants (Some concerns): Selection bias possible due to inclusion of patients with available ECGs.
- Classification of interventions (Low): Interventions clearly defined and protocolized.
- Deviations from intended interventions (Low): Interventions were applied as per protocol.
- Missing data (Some concerns): Missing ECG data for some patients.
- Measurement of outcomes (Low): Outcomes measured consistently with ECGs.
- Selection of the reported result (Low): All relevant outcomes reported.
Transparency
COI Statement Present: TRUE
